Current MIC breakpoints may understate the potential efficacies of carbapenems for treatment of patients with infections caused by strains of Streptococcus pneumoniae that are resistant or of intermediate susceptibility to penicillin.
Edwards
J R
JR
Bradley
J S
JS
Klugman
K P
KP
D015780:Carbapenems / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests; D017063:Outcome Assessment, Health Care; D010403:Penicillin Resistance; D011008:Pneumococcal Infections / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D015780:Carbapenems